New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For PFE;ZTS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 14, 2014
17:14 EDTZTSPershing Square gives quarterly update on stakes
Subscribe for More Information
17:11 EDTZTSZoetis adopts poison pill to protect company from potential hostile takeover
Subscribe for More Information
14:53 EDTPFECVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:25 EDTZTSOptions with increasing implied volatility: BHI DWA ZTS
Subscribe for More Information
07:14 EDTPFEAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
11:28 EDTZTSOptions with increasing implied volatility: CVEO DWA ZTZ
Subscribe for More Information
09:36 EDTZTSZoetis downgraded to Neutral from Long-Term Buy at Hilliard Lyons
Subscribe for More Information
09:33 EDTZTSZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
07:38 EDTPFEBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
November 12, 2014
11:17 EDTPFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:51 EDTZTSOptions with increasing implied volatility: GNW ZTS
Subscribe for More Information
10:07 EDTZTSHigh option volume stocks: DDS FOSL ZTS CMA CLVS CZR
Subscribe for More Information
09:55 EDTZTSZoetis upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
08:13 EDTPFEBoston Biotech to hold a conference
Subscribe for More Information
08:02 EDTPFECredit Suisse to hold a conference
Subscribe for More Information
07:15 EDTZTSSachem reports 0.9% stake in Zoetis
Sachem Head Capital Management reported a 0.9% stake in Zoetis and disclosed a letter agreement pursuant to which the Pershing Square agreed to pay Sachem an incentive fee with respect to its stake in Zoetis. Sachem agreed that for a period of time neither it nor its affiliates will trade with respect to any investment in the company.
07:13 EDTZTSZoetis takeover upside limited at current levels, says William Blair
Subscribe for More Information
07:07 EDTZTSPershing Square reports 8.5% stake in Zoetis
Subscribe for More Information
06:22 EDTZTSZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
06:20 EDTZTSPershing Square confirms 8.5% stake in Zoetis
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use